Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Illumina reported revenue of $1.09 billion for Q1 2023, marking a 1% increase from Q4 2022 but a 11% decrease from Q1 2022. GAAP diluted EPS was $0.02, down from $0.55 a year prior. Non-GAAP diluted EPS was $0.08, compared to $1.07 in Q1 2022. The company reiterated its 2023 revenue guidance of 7% to 10% growth, with Core Illumina expected to grow by 6% to 9% and GRAIL revenue projected between $90 million and $110 million. Illumina anticipates a GAAP diluted loss per share in the range of $(0.28) to $(0.03), while maintaining non-GAAP EPS guidance of $1.25 to $1.50. The company is committed to achieving non-GAAP operating margins of 25% in 2024 and 27% in 2025, also announcing plans for over $100 million in annualized cost savings.
Illumina and Minderoo Foundation announced a $40M AUD partnership aimed at enhancing marine conservation through genomics. This collaboration, initiated in 2022, will span three years and focuses on leveraging scientific methods to deepen understanding of marine ecosystems. A key component includes the installation of a NextSeq™ 2000 Sequencing System aboard the research vessel Pangaea Ocean Explorer. This advanced DNA sequencer will facilitate the study of environmental DNA (eDNA), allowing researchers to better track biodiversity and assess population health within marine environments. The initiative underscores a commitment to conserving marine biodiversity, crucial for national economies and environmental health.
On April 20, 2023, Illumina urged shareholders to support its slate of director nominees ahead of the virtual Annual Meeting on May 25, 2023. The company emphasizes voting with the WHITE proxy card to preserve long-term value and reject Carl Icahn's proposed nominees. Illumina's Board, led by independent chair John W. Thompson, argues that Icahn's nominees lack the qualifications needed to maintain the company's strategic direction. Thompson brings significant experience from his tenure at Microsoft, while CEO Francis A. deSouza has driven substantial revenue growth over the past five years. The company recorded revenue of $198.3 billion and a net income of $72.7 billion as of fiscal year 2022. Shareholders of record as of April 3, 2023, can participate in the vote.